Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03113422
Title Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors PrECOG, LLC.
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Winship Cancer Institute of Emory University Atlanta Georgia 30322 United States Details
Sidney Kimmel Comprehensive Cancer Center at John Hopkins Baltimore Maryland 21205 United States Details
Mayo Clinic Rochester Minnesota 55905 United States Details
Washington University School of Medicine Saint Louis Missouri 63110 United States Details
Rutgers Cancer Institute of NJ New Brunswick New Jersey 08903 United States Details
Fox Chase Philadelphia Pennsylvania 19111 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
University of Virginia Charlottesville Virginia 22908 United States Details
Gunderson Health System Cancer Center La Crosse Wisconsin 54601 United States Details
University of Wisconsin Madison Wisconsin 53792 United States Details
*Shaded cells indicate that there was no data available from for the field